GlassScriptPhysician profile
Connie Lynn Olson
NPI 1255658126
$11,988.89
in general payments reported to CMS, 2019-2025
47 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $857 · 2021: $1,400 · 2022: $2,179 · 2023: $2,429 · 2024: $2,579 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,921 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,921.23 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,951.04 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,433.36 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,240.05 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,152.98 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $923.99 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $804.08 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.38 | 2019-2025 | Jardiance |
| Pfizer INC. | $409.80 | 2019-2025 | |
| Abbott Laboratories | $402.29 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Merck Sharp & Dohme LLC | $267.49 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $250.49 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $234.20 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.73 | 2020-2025 | Xifaxan, Trulance |
| Radius Health, INC. | $202.22 | 2023-2025 | Tymlos |
| Corcept Therapeutics | $179.34 | 2023-2025 | Korlym |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.